🇺🇸 FDA

Company profile · Sponsor

Aldeyra

Aldeyra Therapeutics

ALDX · NYSE pharma LEXINGTON, MA, USA
Pipeline
24
Drugs
2
Patents
8

Quick answer

Aldeyra (ALDX) is a pharma company. headquartered in LEXINGTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker ALDX
Exchange NYSE
Company type pharma
Headquarters LEXINGTON, MA, USA
SEC CIK 0001341235

Pipeline (24)

Search pipeline →

  1. ADX-102 1% Topical Dermal Cream (reproxalap)

    Aldeyra

    Sjogren-Larsson Syndrome

    phase 3 small molecule completed

    1 trial

  2. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  3. ADX-2191 (intravitreal methotrexate 0.8%)

    Aldeyra

    Proliferative Vitreoretinopathy

    phase 3 small molecule completed

    1 trial

  4. ICM ADX-2191 injection

    Aldeyra

    Primary Vitreoretinal Lymphoma

    phase 3 small molecule active

    1 trial

  5. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra

    Allergic Conjunctivitis

    phase 3 small molecule completed

    4 trials

  6. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra

    Dry Eye Disease

    phase 3 small molecule completed

    4 trials

  7. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra

    Dry Eye

    phase 3 small molecule completed

    4 trials

  8. Reproxalap Ophthalmic Solution (0.25%) QID

    Aldeyra

    Dry Eye

    phase 3 small molecule completed

    1 trial

  9. ADX-102 Ophthalmic Drops (0.5%)

    Aldeyra

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  10. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  11. ADX-2191

    Aldeyra

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  12. ADX-629

    Aldeyra

    Ethanol Intoxication

    phase 2 small molecule completed

    1 trial

  13. ADX-629

    Aldeyra

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial

  14. ADX-629

    Aldeyra

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  15. ADX-629

    Aldeyra

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  16. ADX-629

    Aldeyra

    Atopic Asthma

    phase 2 small molecule completed

    1 trial

  17. ADX-629

    Aldeyra

    Chronic Cough

    phase 2 small molecule completed

    1 trial

  18. ADX-629

    Aldeyra

    Covid19

    phase 2 small molecule completed

    1 trial

  19. ADX-629 (Open-label)

    Aldeyra

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  20. Active topical NS2 1% dermatologic cream

    Aldeyra

    Sjögren-Larsson Syndrome

    phase 2 small molecule completed

    1 trial

  21. NS2

    Aldeyra

    Non-infectious Anterior Uveitis

    phase 2 small molecule completed

    1 trial

  22. NS2 Ophthalmic Drops (0.5%)

    Aldeyra

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  23. Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

    Aldeyra

    Dry Eye

    phase 2 small molecule completed

    1 trial

  24. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra

    Dry Eye Syndrome

    phase 2 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. isoetharine hydrochloride

    ISOETHARINE HYDROCHLORIDE

    INHALATION approved

  2. metaproterenol sulfate

    ALUPENT

    ORAL approved

Patents (8)

Search patents →

  1. US 12240816

    Deuterated compounds and uses thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12128013

    Toxic aldehyde related diseases and treatment

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12097188

    Compositions and methods for the treatment of macular degeneration

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12064516

    Pharmaceutical formulations and uses thereof

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12029735

    Polymorphic compounds and uses thereof

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12006298

    Polymorphic compounds and uses thereof

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12005060

    Ophthalmic formulations of methotrexate

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12005061

    Ophthalmic formulations of methotrexate

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aldeyra?

Aldeyra (ALDX) is a pharma company. headquartered in LEXINGTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does Aldeyra sponsor?

We track 24 ClinicalTrials.gov-linked programs for Aldeyra, including ADX-102 1% Topical Dermal Cream (reproxalap) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aldeyra company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.